Neurogene Inc. develops genetic medicines for rare neurological diseases, with recurring updates centered on NGN-401, its investigational AAV9 gene therapy for Rett syndrome. Company news covers the EXACT™ transgene regulation technology, intracerebroventricular delivery for CNS-targeted gene therapy, clinical data from NGN-401 studies, and regulatory designations granted by U.S., European, and U.K. agencies.
Other recurring Neurogene developments include financial results, corporate presentations, scientific conference participation, board and executive appointments, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). The company also identifies NGN-101 as a conventional gene therapy development candidate for CLN5 Batten disease.
Neurogene (Nasdaq: NGNE) will present NGN-401 Rett syndrome gene therapy data at the ESGCT congress taking place October 27–30, 2026. The meeting will be held in Hamburg, Germany.
Presentations will cover new preclinical data on how quickly single-stranded AAV, a viral delivery vehicle, produces MECP2 gene expression, alongside early time-to-response observations from the Phase 1/2 trial. Other work evaluates approaches to regulating expression in individual cells, including Neurogene’s EXACT technology, in a preclinical Rett syndrome model. Talks and posters on October 28–29 will also address delivery into the brain’s fluid-filled spaces and provide an overview of EXACT.
Neurogene (NGNE) announced stock option inducement grants covering 8,340 common shares for five new employees under its 2025 Inducement Plan.
The Compensation Committee approved the grants on October 5, 2026, under Nasdaq Listing Rule 5635(c)(4). The exercise price equals the stock’s closing price on the grant date. Options vest over four years: 25 percent on the first anniversary of the vesting commencement date, then 1/48 of the total award monthly over the following three years, subject to continued employment through each vesting date.
Neurogene (NGNE)/b) will participate in the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15 at 1:00 p.m. ET.Company management is scheduled for a fireside chat and investor meetings. A live webcast of the fireside chat will be available through the Investor Relations section of Neurogene’s website under events, with a replay accessible there for a limited time.
Neurogene (NGNE) granted non-qualified stock options to purchase a total of 38,330 shares of common stock to two new employees on September 1, 2026. These awards were approved by the Board’s Compensation Committee under the company’s 2025 Inducement Plan and are intended as inducement grants under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price equal to the closing price of Neurogene’s common stock on the grant date. They vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment.
Neurogene (Nasdaq: NGNE) reported second quarter 2026 results and progress on its NGN-401 Rett syndrome gene therapy. Phase 1/2 data (N=10) showed 100% of participants improved on CGI-I and gained ≥1 developmental milestone, averaging 4.7 milestones, with continued gains through 30 months and no plateau or milestone loss as of June 16, 2026.
According to Neurogene, 7 of 10 participants gained ≥2 milestones and improved across ≥2 Rett domains, with significant benefits on RSGMS and RSHFS (p<0.001). NGN-401 was generally well-tolerated at 1E15 vg in 35 participants across trials as of August 10, 2026. All 25 Embolden registrational trial participants have been dosed, with topline data expected in 2H 2027, and a PPQ manufacturing campaign initiated in July 2026 to support a planned BLA, with PPQ runs targeted for completion by year-end 2026.
The company completed an oversubscribed follow-on offering for approximately $144 million in gross proceeds. Cash, cash equivalents and short-term investments were $225.4 million at June 30, 2026, rising to a pro forma $360.2 million with July offering proceeds, which Neurogene expects to fund operations into 1Q 2029. Second quarter 2026 R&D and G&A expenses were $25.5 million and $11.2 million, respectively, and net loss was $34.5 million.
Neurogene (Nasdaq: NGNE) announced that its Board’s Compensation Committee approved non-qualified stock option inducement grants covering an aggregate of 12,555 shares of common stock for four new employees, effective August 3, 2026, under the company’s 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
According to Neurogene, the options have an exercise price equal to the closing price on the grant date. The awards vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment.
Newleos Therapeutics, a clinical-stage biotech focused on neuropsychiatric disorders, appointed Rohan Palekar to its Board of Directors and elected him Chairman. Christoph Westphal, who has served as Executive Chairman since Newleos’ founding, will step down from that role but remain on the Board representing founding investor Longwood Fund.
According to Newleos, Palekar brings over 30 years of biotechnology and pharmaceutical experience, including serving as founding CEO of 89bio, where he led multiple programs from preclinical through Phase 3 in liver and cardiometabolic diseases; 89bio was acquired by Roche in 2025 for up to $3.5 billion. He previously was President and CEO of Avanir Pharmaceuticals, which was acquired by Otsuka Pharmaceutical in 2015, and Chief Commercial Officer at Medivation, after senior roles at Johnson & Johnson. Newleos highlights his CNS and company-building background as it approaches key clinical inflection points in ongoing anxiety trials. Palekar also serves on the board of Neurogene (Nasdaq: NGNE) and previously served on Neoleukin Therapeutics’ board.
Neurogene (Nasdaq: NGNE) granted non-qualified stock options to purchase an aggregate of 96,450 shares of common stock to six new employees under its 2025 Inducement Plan, effective July 6, 2026.
The options have an exercise price equal to the Grant Date closing price and vest over four years, subject to continued employment.
Neurogene (Nasdaq: NGNE) priced a public offering of 3,500,000 common shares at $30.00 each and pre-funded warrants for up to 666,666 shares at $29.999999 per warrant. Expected gross proceeds are about $125 million before fees. Closing is expected on July 2, 2026, with underwriters holding a 30-day option to buy up to 624,999 additional shares.
Neurogene (Nasdaq: NGNE) began a proposed public offering of common stock and, for certain investors, pre-funded warrants. Underwriters are expected to receive a 30-day option to buy more shares. All securities are offered by Neurogene, with proceeds planned for NGN-401 clinical development, pre-commercial activities, and general corporate purposes.